HTGF has participated in a seed round for Kumovis, a spinout of Technical University of Munich that is working on 3D printers for medical technology.

Qpex Biopharma, which was spun off to develop The Medicines Company's anti-infective drug assets, has received $33m in its series A round.

Legend Holdings, Eli Lilly, Ping An, China Life and Taikang-backed Innovent Biologics priced its shares near the top of the range of to raise $421m.

Pfizer has joined forces with Bain Capital to establish Cerevel Therapeutics, which has secured $350m in funding to target central nervous system disorders.

Seventure Partners has injected $5.2m into the Sanger Institute spinout, which has now raised $15.2m from investors also including IP Group and Cambridge Innovation Capital.

Fosun Pharma has committed series A funding to Glycotest, a liver disease diagnostics developer based on research at Baruch S. Blumberg Institute and Drexel University.

University of Washington has established RNA sequencing technology developer Split Biosciences, which has raised $1.2m in seed funding from unnamed investors.

Orphan disease drug developer PhaseBio Pharmaceuticals, which is commercialising research from Duke University, cut the price of its shares sharply pre-offering.

Orphan disease drug developer PhaseBio Pharmaceuticals, which counts Johnson & Johnson, Astellas and AstraZeneca as investors, cut the price of its shares sharply pre-offering.

GV-backed care manager Aledade has doubled the size of its latest funding round to $46m and increased its overall funding to $100m.